Latham & Watkins LLP represented VistaGen in the transaction. VistaGen Therapeutics, Inc. (VistaGen) closed its underwritten public offering of 63 million shares of its common stock,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
